DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Molecular Genetics of Retinal Degenerations

Information source: National Institutes of Health Clinical Center (CC)
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Retinal Degeneration; Retinitis Pigmentosa

Phase: N/A

Status: Recruiting

Sponsored by: National Eye Institute (NEI)

Overall contact:
Patient Recruitment and Public Liaison Office, Phone: (800) 411-1222, Email: prpl@mail.cc.nih.gov

Summary

This multinational study will investigate the inheritance of genetic retinal degeneration in families of different nationalities and ethnic backgrounds in order to identify the genes that, when altered, cause retinal degeneration. The retina is a light-sensitive membrane lining the back part of the eye. It relays vision signals to the brain, which the brain interprets into sight. When the retina degenerates, vision is altered and possibly lost. The findings of this study should help improve diagnosis and methods of treatment for these disorders. Participating institutions include: the National Institutes for Health in Bethesda, Maryland; the University of Miami in Florida; the Casey Eye Institute in Portland, Oregon; the Byrd Health Sciences Center in Morgantown, West Virginia; the University of Texas Southwestern Medical School in Dallas, Texas; the University of Tennessee Health Sciences Center in Memphis; the Prasad Eye Institute in Hyderabad, India; National Center of Excellence in Molecular Biology in Lahore, Pakistan; and the Jules Gonin Hospital in Lausanne, Switzerland.

Patients with retinitis pigmentosa and closely related diseases such as Usher syndrome, snowflake vitreoretinal dystrophy and Bietti crystalline dystrophy may be eligible for this study. Participants undergo the following tests and procedures:

- Medical and surgical history, including family history of vision problems.

- Examination to clarify the type of retinal degeneration.

- Eye examination, including tests of color vision, field of vision and ability to see in

the dark

- Electroretinogram to test the function of visual cells. For this test, the patient sits

in a dark room for 30 minutes with his or her eyes patched. Then, a small electrode (silver disk) is taped to the forehead and the eye patches are removed. The surface the eyes is numbed with eye drops, and contact lenses are placed on the eyes. The patient looks inside a large dark globe that emits a series of light flashes. Then a light is turned on inside the globe and more lights flash. The contact lenses sense small electrical signals generated by the retina when the light flashes.

- Hearing tests for patients with a personal or family history of deafness. Tests include

an audiogram, ear examination and test of middle ear function. For middle ear function testing, the patient feels a little air pressure change for a moment and hears some tones. Another test requires the patient to sit quietly with electrodes on the head, forehead and earlobes.

- Balance testing, including walking in a straight line, standing with eyes closed in the

dark and other tests of coordination, and caloric testing. For the caloric testing, any ear wax in the ear canal is removed before the test begins. Then, electrodes are placed on the skin near the eyes and on the forehead. A small amount of cool (sometimes cold) or warm water is instilled into each ear canal, first one and then the other.

- Blood sample collection for genetic testing.

Clinical Details

Official title: Molecular Genetics of Retinal Degenerations

Study design: N/A

Detailed description: This project, Molecular Genetics of Retinal Degenerations will study the inheritance of genetic retinal degenerations, both Mendelian and complex, in families of many nationalities and ethnic backgrounds in order to identify the genes that, when mutated, cause retinal degenerations and the pathophysiology through which they act. The number of subjects to be enrolled has no logical upper limit, but will be at least 250. The study consists of ascertaining individuals, and especially families with multiple individuals, affected by retinal degenerations including retinitis pigmentosa (RP) and also other closely related retinal degenerations such as Usher syndrome (USH) and Bietti crystalline dystrophy (BCD). These patients and their families will undergo detailed ophthalmological examinations and, where indicated, additional non-investigational examinations to characterize their retinal degeneration and determine their affectation status. A blood sample will be collected from each individual for isolation of DNA and in some individuals for lymphoblastoid transformation to establish a renewable source of DNA. Linkage analysis, physical mapping, and mutational screening will be carried out to identify the specific gene and the mutations in it that are associated with retinal degenerations in this family. If necessary, the gene product will be characterized biochemically. The principle investigator is James Fielding Hejtmancik at the OMGS/OGVFB/NEI. Associate investigators at the OGVFB/NEI include Dr. Raphael Caruso, and Dr. Benjamin Rubin. Associate investigators at collaborating institutions include Dr. Xuezhong Liu (University of Miami), Dr. Richard Welleber (University of Oregon), Dr. Monique Leys (West Virginia University), Dr. Chitra Kannabiran (L.. V. Prasad Eye Institute, Hyderabad, India), Dr. S. Riazuddin (Centre for Excellence in Molecular Biology, Lahore, Pakistan), Dr. Francis Muniere (Jules Gonin Eye Hospital, Lusanne, Switzerland), Dr. Albert Edwards (UT Southwestern Med. Ctr), and Dr. Allesandro Iannaccone (U Tenn Health Sci Ctr).

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

- INCLUSION CRITERIA:

Patients that meet diagnostic criteria for specific retinal degenerations will be recruited from the NEI and collaborating clinics.

In addition, this protocol will include patients with other retinal degenerations, including retinitis pigmentosa and Bietti crystalline dystrophy, which have been excluded from the Gyrate atrophy protocol EI 78-001, in which they were formerly included.

Locations and Contacts

Patient Recruitment and Public Liaison Office, Phone: (800) 411-1222, Email: prpl@mail.cc.nih.gov

University of Punjabv, Lahore, Pakistan; Recruiting

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States; Recruiting

Harvard Medical School, Boston, Massachusetts 02115, United States; Recruiting

Casey Eye Institute, Portland, Oregon, United States; Recruiting

UT Southwestern Medical School, Dallas, Texas, United States; Recruiting

Additional Information

NIH Clinical Center Detailed Web Page

Related publications:

Smith RJ, Pelias MZ, Daiger SP, Keats B, Kimberling W, Hejtmancik JF. Clinical variability and genetic heterogeneity within the Acadian Usher population. Am J Med Genet. 1992 Aug 1;43(6):964-9.

Keats BJ, Todorov AA, Atwood LD, Pelias MZ, Hejtmancik JF, Kimberling WJ, Leppert M, Lewis RA, Smith RJ. Linkage studies of Usher syndrome type 1: exclusion results from the Usher syndrome consortium. Genomics. 1992 Nov;14(3):707-14.

Smith RJ, Lee EC, Kimberling WJ, Daiger SP, Pelias MZ, Keats BJ, Jay M, Bird A, Reardon W, Guest M, et al. Localization of two genes for Usher syndrome type I to chromosome 11. Genomics. 1992 Dec;14(4):995-1002.

Starting date: September 2005
Last updated: July 18, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012